CD133 Regulation in Prostate Cancer and Epithelial Differentiation
Author Information
Author(s): Pellacani Davide, Packer Richard J, Frame Fiona M, Oldridge Emma E, Berry Paul A, Labarthe Marie-Christine, Stower Michael J, Simms Matthew S, Collins Anne T, Maitland Norman J
Primary Institution: YCR Cancer Research Unit, Department of Biology, University of York
Hypothesis
The regulation of CD133 expression is influenced by epigenetic mechanisms, particularly DNA methylation, in prostate cancer and epithelial differentiation.
Conclusion
CD133 expression is regulated by DNA methylation in prostate cell lines but is independent of DNA methylation in primary prostate tissues.
Supporting Evidence
- CD133 expression is repressed by DNA methylation in prostate cell lines.
- In primary prostate cancer tissues, regulation of CD133 is independent of DNA methylation.
- Chromatin structure plays a crucial role in regulating CD133 expression.
Takeaway
This study shows that how a specific marker for stem cells, called CD133, is controlled can be very different in lab-grown cells compared to real tissues from patients.
Methodology
The study used DNA methylation analysis, qRT-PCR for measuring CD133 expression, and chromatin structure determination by ChIP.
Potential Biases
Potential bias due to the reliance on cell lines which may not accurately reflect in vivo conditions.
Limitations
The study primarily focuses on cell lines and may not fully represent the complexity of primary tissues.
Participant Demographics
Human prostate tissues from patients with benign prostatic hyperplasia and prostate cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website